Sensus Healthcare Q2 revenue misses expectations

Overview

• Sensus Healthcare Q2 revenue falls to $7.3 mln, missing analyst expectations

• Adjusted EBITDA for Q2 was negative $1.8 mln, missing analyst estimates

• Company reported a net loss of $1.0 mln, or $0.06 per share

Outlook

• Company expects Medicare fee schedule changes to impact SRT adoption in 2026

Result Drivers

• REVENUE DECLINE - Revenue fell due to fewer unit sales to a large customer, partially offset by growth in recurring revenue from Fair Deal Agreements

• INCREASED FDA VOLUME - FDA treatment volume rose 27% sequentially, indicating traction in this area

• STRATEGIC PARTNERSHIP - Partnership with Radiology Oncology Systems aims to boost distribution in hospital systems and oncology departments

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Sensus Healthcare Inc is $11.00, about 51.5% above its August 6 closing price of $5.33

• The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release: ID:nBw1JLl9Za